|
|
Article: Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer.(Clinical report)
- Article from:
- Business Wire
- Article date:
- June 2, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- First Antibody That Specifically Inhibits VEGF to Show Improvement in a Phase III Kidney Cancer Trial -
CHICAGO -- Genentech, Inc. (NYSE:DNA) today announced that a Roche-sponsored, randomized placebo-controlled Phase III clinical study of Avastin([R]) (bevacizumab) in combination with interferon alfa-2a therapy increased the median time patients with first-line metastatic renal cell carcinoma (mRCC) lived without their cancer growing or spreading as defined by progression-free survival (PFS). Patients receiving Avastin plus interferon alfa-2a therapy experienced a 59 percent improvement in PFS (based on a hazard ratio of 0.63) compared to those receiving ...